X chromosome aneuploidies and schizophrenia: association analysis and phenotypic characterization.


Journal

Psychiatry and clinical neurosciences
ISSN: 1440-1819
Titre abrégé: Psychiatry Clin Neurosci
Pays: Australia
ID NLM: 9513551

Informations de publication

Date de publication:
Dec 2022
Historique:
revised: 30 08 2022
received: 31 05 2022
accepted: 01 09 2022
pubmed: 9 9 2022
medline: 6 12 2022
entrez: 8 9 2022
Statut: ppublish

Résumé

The aims of the present study were: (i) to examine the association between schizophrenia (SCZ) and 47, XXY or 47, XXX in a large case-control sample; and (ii) to characterize the clinical features of patients with SCZ with these X chromosome aneuploidies. To identify 47, XXY and 47, XXX, array comparative genomic hybridization (aCGH) was performed in 3188 patients with SCZ and 3586 controls. We examined the association between 47, XXY and 47, XXX and SCZ in males and females separately using exact conditional tests to control for platform effects. Clinical data were retrospectively examined for patients with SCZ with X chromosome aneuploidies. Of the analyzed samples, 3117 patients (97.8%) and 3519 controls (98.1%) passed our quality control. X chromosome aneuploidies were exclusively identified in patients: 47, XXY in seven patients (0.56%), 47, XXX in six patients (0.42%). Statistical analysis revealed a significant association between SCZ and 47, XXY (P = 0.028) and 47, XXX (P = 0.011). Phenotypic data were available from 12 patients. Treatment-resistance to antipsychotics and manic symptoms were observed in six patients each (four with 47, XXY and two with 47, XXX for both), respectively. Statistical analysis revealed that treatment-resistance to antipsychotics, mood stabilizer use, and manic symptoms were significantly more common in patients with 47, XXY than in male patients without pathogenic copy number variations. These findings indicate that both 47, XXY and 47, XXX are significantly associated with risk for SCZ. Patients with SCZ with 47, XXY may be characterized by treatment-resistance and manic symptoms.

Identifiants

pubmed: 36073611
doi: 10.1111/pcn.13474
pmc: PMC10086948
doi:

Substances chimiques

Antipsychotic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

667-673

Subventions

Organisme : Japan Agency for Medical Research and Development
ID : JP21wm0525024
Organisme : Japan Agency for Medical Research and Development
ID : JP21tm0424220
Organisme : Japan Agency for Medical Research and Development
ID : JP21wm0425012
Organisme : Japan Agency for Medical Research and Development
ID : JP19dm0207075
Organisme : Japan Agency for Medical Research and Development
ID : JP19ak0101113
Organisme : Japan Agency for Medical Research and Development
ID : JP19ek0109411
Organisme : Japan Agency for Medical Research and Development
ID : JP21wm0425007
Organisme : Japan Agency for Medical Research and Development
ID : JP21wm0425008
Organisme : Japan Agency for Medical Research and Development
ID : JP20ek0109488
Organisme : Japan Agency for Medical Research and Development
ID : JP19km0405216
Organisme : Japan Agency for Medical Research and Development
ID : JP21dk0307103
Organisme : Japan Agency for Medical Research and Development
ID : JP22tm0424222
Organisme : Japan Society for the Promotion of Science
ID : 17H05090
Organisme : Japan Society for the Promotion of Science
ID : 18H04040
Organisme : Japan Society for the Promotion of Science
ID : 21K07543
Organisme : Japan Society for the Promotion of Science
ID : 20K07942
Organisme : Japan Society for the Promotion of Science
ID : 19K17087
Organisme : Japan Society for the Promotion of Science
ID : 15K19720
Organisme : Japan Society for the Promotion of Science
ID : 21H00194
Organisme : Japan Society for the Promotion of Science
ID : 18K19511
Organisme : Japan Society for the Promotion of Science
ID : 21H04815
Organisme : SENSHIN Medical Research Foundation
Organisme : Uehara Memorial Foundation
Organisme : Ministry of Health, Labour and Welfare
Organisme : Ministry of Education, Culture, Sports, Science and Technology

Informations de copyright

© 2022 The Authors. Psychiatry and Clinical Neurosciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology.

Références

Nat Genet. 2017 Jan;49(1):27-35
pubmed: 27869829
Oncotarget. 2017 Jan 17;8(3):3969-3979
pubmed: 27992373
Curr Opin Psychiatry. 2019 Mar;32(2):79-84
pubmed: 30689602
N Engl J Med. 2012 Oct 4;367(14):1321-31
pubmed: 22970919
Hum Genome Var. 2019 Jun 18;6:28
pubmed: 31240104
Hum Mol Genet. 2013 Nov 15;22(22):4485-501
pubmed: 23813976
Curr Opin Genet Dev. 2021 Jun;68:18-25
pubmed: 33454514
Psychiatr Clin North Am. 2010 Mar;33(1):35-66
pubmed: 20159339
Mol Neuropsychiatry. 2018 Oct;4(2):83-89
pubmed: 30397596
Br J Psychiatry. 2014 Feb;204(2):108-14
pubmed: 24311552
J ECT. 2013 Sep;29(3):e36-7
pubmed: 23965608
Nature. 2008 Sep 11;455(7210):237-41
pubmed: 18668038
Mol Psychiatry. 2014 Jul;19(7):762-73
pubmed: 24776740
Lancet Neurol. 2014 Mar;13(3):306-18
pubmed: 24556008
Schizophr Bull. 1994;20(3):495-505
pubmed: 7973466
Mol Psychiatry. 2015 Sep;20(9):1028-9
pubmed: 26055425
Neuropsychopharmacology. 2019 Jan;44(1):9-21
pubmed: 30127341
Med J Aust. 2011 Jan 3;194(1):24-8
pubmed: 21449864
Mol Psychiatry. 2017 Mar;22(3):430-440
pubmed: 27240532
J Psychiatr Res. 2014 Jan;48(1):128-30
pubmed: 24139812
Front Hum Neurosci. 2017 Jun 22;11:322
pubmed: 28690503
Schizophr Res. 1999 Nov 9;40(1):43-7
pubmed: 10541006
World J Biol Psychiatry. 2017 Oct;18(7):492-505
pubmed: 28112043
Annu Rev Genomics Hum Genet. 2011;12:121-44
pubmed: 21639796
Schizophr Bull. 2022 Dec 01;:
pubmed: 36454006
Cell Rep. 2018 Sep 11;24(11):2838-2856
pubmed: 30208311
Nat Rev Neurosci. 2010 Jun;11(6):402-16
pubmed: 20485365
J Clin Invest. 2013 Nov;123(11):4557-63
pubmed: 24177465
Nature. 2008 Sep 11;455(7210):232-6
pubmed: 18668039
Schizophr Res. 2007 Jul;93(1-3):399-402
pubmed: 17459660
Prog Neurobiol. 2012 Oct;99(1):81-91
pubmed: 22813947
Biol Psychiatry. 2022 Sep 1;92(5):362-374
pubmed: 35667888
Eur J Hum Genet. 2010 Mar;18(3):265-71
pubmed: 19568271
Am J Psychiatry. 2002 Mar;159(3):493-4
pubmed: 11870023
Arch Gen Psychiatry. 1988 Sep;45(9):789-96
pubmed: 3046553
Pediatrics. 2009 May;123(5):e865-70
pubmed: 19364768
Nucleic Acids Res. 2010 Apr;38(7):e94
pubmed: 20071741

Auteurs

Itaru Kushima (I)

Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Medical Genomics Center, Nagoya University Hospital, Nagoya, Japan.

Branko Aleksic (B)

Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Hiroki Kimura (H)

Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Masahiro Nakatochi (M)

Public Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Tzuyao Lo (T)

Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Masashi Ikeda (M)

Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan.

Makoto Arai (M)

Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.

Ryota Hashimoto (R)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.

Shusuke Numata (S)

Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University, Tokushima, Japan.

Yasunobu Okamura (Y)

Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai, Japan.
Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.

Taku Obara (T)

Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.

Toshiya Inada (T)

Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Norio Ozaki (N)

Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Institute for Glyco-core Research (iGCORE), Nagoya University, Nagoya, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH